Skip to main content

REPARACION CARDIACA UTILIZANDO INGENIERIA TISULAR Y/O EXOSOMAS: MECANISMOS IMPLICADOS Y EFICACIA TERAPEUTICA EN UN MODELO ANIMAL DE INFARTO DE MIOCARDIO

SAF2017-83734-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE NAVARRA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Delivery of cardiovascular progenitors with biomimetic microcarriers reduces adverse ventricular remodeling in a rat model of chronic myocardial infarction

  • Garbayo, Elisa
  • Ruiz-Villalba, Adrián
  • Hernández, Silvia C.
  • Saludas, Laura
  • Abizanda, Gloria
  • Pelacho, Beatriz
  • Roncal Mancho, Carmen
  • Sánchez, B. (Belén)
  • Palacios, Itziar
  • Prósper, Felipe
  • Blanco-Prieto, María J.
Despite tremendous progress in cell-based therapies for heart repair, many challenges still exist. To enhance the therapeutic potential of cell therapy one approach is the combination of cells with biomaterial delivery vehicles. Here, we developed a biomimetic and biodegradable micro-platform based on polymeric microparticles (MPs) capable of maximizing the therapeutic potential of cardiac progenitor cells (CPCs) and explored its efficacy in a rat model of chronic myocardial infarction. The transplantation of CPCs adhered to MPs within the infarcted myocardial microenvironment improved the long-term engraftment of transplanted cells for up to one month. Furthermore, the enhancement of cardiac cellular retention correlated with an increase in functional recovery. In consonance, better tissue remodeling and vasculogenesis were observed in the animals treated with cells attached to MPs, which presented smaller infarct size, thicker right ventricular free wall, fewer deposition of periostin and greater density of vessels than animals treated with CPCs alone. Finally, we were able to show that part of this beneficial effect was mediated by CPC-derived extracellular vesicles (EVs). Taken together, these findings indicate that the biomimetic microcarriers support stem cell survival and increase cardiac function in chronic myocardial infarction through modulation of cardiac remodeling, vasculogenesis and CPCs-EVs mediated therapeutic effects. The biomimetic microcarriers provide a solution for biomaterial-assisted CPC delivery to the heart., This work was supported by the FEDER/Ministry of Science and Innovation-State Research Agency/SAF2017-83734-R and funds from the ISCIII and co-financed by FEDER (PI19/00501), Red TERCEL RETIC RD16/0011/0005 and MINECO (Program RETOS Cardiomesh RTC-2016-4911-1), ERANET II (Nanoreheart AC15/00050), and EU's H2020 Programme for research, technological development and demonstration under grant agreement BRAV¿-874827. Elisa Garbayo is supported by a FSE/Ministry of Science and Innovation-State Research Agency RYC2018-025897-I. Adrian Ruiz-Villalba is supported by the Spanish Ministry of Sciences and Innovations FSE/MINECO-AEI(IJCI-2016-30254), and the Spanish Ministerio de Ciencia, Innovación y Universidades (grant RTI2018-095410-BI00). We thank Filippo Roli and Elena Iglesias for technical support.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Extracellular vesicle-based therapeutics for heart repair

  • Saludas, Laura
  • Oliveira, Cláudia C.
  • Roncal Mancho, Carmen
  • Ruiz-Villalba, Adrián
  • Prósper, Felipe
  • Garbayo, Elisa
  • Blanco-Prieto, María J.
Extracellular vesicles (EVs) are constituted by a group of heterogeneous membrane vesicles secreted by most cell types that play a crucial role in cell¿cell communication. In recent years, EVs have been postulated as a relevant novel therapeutic option for cardiovascular diseases, including myocardial infarction (MI), partially outperforming cell therapy. EVs may present several desirable features, such as no tumorigenicity, low immunogenic potential, high stability, and fine cardiac reparative efficacy. Furthermore, the natural origin of EVs makes them exceptional vehicles for drug delivery. EVs may overcome many of the limitations associated with current drug delivery systems (DDS), as they can travel long distances in body fluids, cross biological barriers, and deliver their cargo to recipient cells, among others. Here, we provide an overview of the most recent discoveries regarding the therapeutic potential of EVs for addressing cardiac damage after MI. In addition, we review the use of bioengineered EVs for targeted cardiac delivery and present some recent advances for exploiting EVs as DDS. Finally, we also discuss some of the most crucial aspects that should be addressed before a widespread translation to the clinical arena., This work was funded by Spanish Ministry of Economy and Competitiveness (SAF2017-83734-R), the 7th EuroNanoMed-II call for proposals, project NanoHeart n°ANR-16-ENM2-0005-01 and Nano ReHeart AC15/0050. C.O. is supported by the European Union‘s Horizon 2020 research and innovation programme Under the Marie Sklodowska-Curie grant agreement No 713721. A.R.V. was supported by a Juan de La Cierva Fellowship (IJCI-2016-30254) and is supported by a “I Plan Propio de Incorporación de Doctores” from the University of Málaga, and by the Spanish Ministerio de Ciencia y Universidades (RTI2018-095410-B-I00). E. Garbayo is supported by a “Ramon y Cajal Fellowship” (RYC2018-025897-I).